Page 49 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
P. 49
SPARTAN Secondary Endpoint: OS (Interim Analysis)
• 30% reduction in the risk of death
APA, not reached
PBO, 39.0 mo
(median)
APA = apalutamide; OS = overall survival; PBO = placebo.
Smith MR, et al. N Engl J Med. 2018;378:1408-18.
49
